NONCONSOLIDATED AFFILIATES	6 Months Ended
Jun. 30, 2026
Equity Method Investments and Joint Ventures [Abstract]
NONCONSOLIDATED AFFILIATES	NONCONSOLIDATED AFFILIATES The Company's investments in affiliates accounted for using the equity method ("nonconsolidated affiliates") are recorded in "Investments and noncurrent receivables" in the interim Condensed Consolidated Balance Sheets. The Company's net investment in nonconsolidated affiliates at June 30, 2026 and December 31, 2025 was $458 million and $111 million, respectively. Sales to nonconsolidated affiliates represented less than 1 percent of total net sales for the three and six months ended June 30, 2026 and 2025. There were no purchases from nonconsolidated affiliates for the three and six months ended June 30, 2026 and 2025. The Company maintained an ownership interest in three nonconsolidated affiliates at June 30, 2026. Arclin Equity Interest and Note Receivable As a result of the Aramids divestiture which closed on April 1, 2026, the Company acquired approximately a 16 percent non-controlling equity interest in Arclin. As part of this transaction, DuPont received a note receivable of $300 million. The financial results of Arclin, subsequent to the transaction date, will be included in DuPont's Consolidated Financial Statements with a three-month lag, using the equity method of accounting and with intercompany profits eliminated in accordance with DuPont’s accounting policy. As such, no equity earnings of non-consolidated affiliates were recorded for the three and six months ended June 30, 2026. The amounts related to the Arclin equity interest will be recorded within Corporate. As of June 30, 2026, the carrying value of the equity interest was $325 million. Refer to Note 3 for further information. For the three and six months ended June 30, 2026, the Company recognized non-cash interest income related to the Aramids Note Receivable of $5 million. This income was reported in "Sundry income (expense) – net" on the interim Consolidated Statements of Operations, and accreted to the carrying value of the note receivable. The carrying value of the note receivable as of June 30, 2026 was $188 million, recorded in "Investments and noncurrent receivables" in the interim Condensed Consolidated Balance Sheets. Derby Equity Interest and Note Receivable As a result of the Delrin® divestiture on November 1, 2023, the Company acquired a 19.9 percent non-controlling equity interest in Derby Group Holdings LLC ("Derby"). As part of this transaction, DuPont received a note receivable of $350 million (the "Derby Note Receivable"). The financial results of Derby, subsequent to the transaction date, are included in DuPont's interim Consolidated Financial Statements with a three-month lag using the equity method of accounting and with intercompany profits eliminated in accordance with DuPont’s accounting policy. The Company recorded a gain of $8 million for both the three months ended June 30, 2026 and 2025. The Company recorded a gain of $7 million and loss of $6 million for the six months ended June 30, 2026 and 2025, respectively. These gains and losses were reported in "Equity in earnings (losses) of nonconsolidated affiliates" in the interim Consolidated Statements of Operations. The amounts related to the Derby equity interest are recorded within Corporate. The carrying values of the equity interest as of June 30, 2026 and December 31, 2025 were $132 million and $111 million, respectively. The Company recognized non-cash interest income related to the Derby Note Receivable of $8 million and $6 million for the three months ended June 30, 2026 and 2025, respectively, and $15 million and $13 million for the six months ended June 30, 2026 and 2025, respectively. This income was reported in "Sundry income (expense) – net" on the interim Consolidated Statements of Operations, and accreted to the carrying value of the note receivable. The carrying values of the note receivable as of June 30, 2026 and December 31, 2025 were $297 million and $265 million, respectively, recorded in "Investments and noncurrent receivables" in the interim Condensed Consolidated Balance Sheets.

The Company's investments in affiliates accounted for using the equity method ("nonconsolidated affiliates") are recorded in "Investments and noncurrent receivables" in the interim Condensed Consolidated Balance Sheets. The Company's net investment in nonconsolidated affiliates at June 30, 2026 and December 31, 2025 was $458 million and $111 million, respectively.

Sales to nonconsolidated affiliates represented less than 1 percent of total net sales for the three and six months ended June 30, 2026 and 2025. There were no purchases from nonconsolidated affiliates for the three and six months ended June 30, 2026 and 2025. The Company maintained an ownership interest in three nonconsolidated affiliates at June 30, 2026.

As a result of the Aramids divestiture which closed on April 1, 2026, the Company acquired approximately a 16 percent non-controlling equity interest in Arclin. As part of this transaction, DuPont received a note receivable of $300 million. The financial results of Arclin, subsequent to the transaction date, will be included in DuPont's Consolidated Financial Statements with a three-month lag, using the equity method of accounting and with intercompany profits eliminated in accordance with DuPont’s accounting policy. As such, no equity earnings of non-consolidated affiliates were recorded for the three and six months ended June 30, 2026. The amounts related to the Arclin equity interest will be recorded within Corporate. As of June 30, 2026, the carrying value of the equity interest was $325 million. Refer to Note 3 for further information.

For the three and six months ended June 30, 2026, the Company recognized non-cash interest income related to the Aramids Note Receivable of $5 million. This income was reported in "Sundry income (expense) – net" on the interim Consolidated Statements of Operations, and accreted to the carrying value of the note receivable. The carrying value of the note receivable as of June 30, 2026 was $188 million, recorded in "Investments and noncurrent receivables" in the interim Condensed Consolidated Balance Sheets.

As a result of the Delrin® divestiture on November 1, 2023, the Company acquired a 19.9 percent non-controlling equity interest in Derby Group Holdings LLC ("Derby"). As part of this transaction, DuPont received a note receivable of $350 million (the "Derby Note Receivable"). The financial results of Derby, subsequent to the transaction date, are included in DuPont's interim Consolidated Financial Statements with a three-month lag using the equity method of accounting and with intercompany profits eliminated in accordance with DuPont’s accounting policy. The Company recorded a gain of $8 million for both the three months ended June 30, 2026 and 2025. The Company recorded a gain of $7 million and loss of $6 million for the six months ended June 30, 2026 and 2025, respectively. These gains and losses were reported in "Equity in earnings (losses) of nonconsolidated affiliates" in the interim Consolidated Statements of Operations. The amounts related to the Derby equity interest are recorded within Corporate. The carrying values of the equity interest as of June 30, 2026 and December 31, 2025 were $132 million and $111 million, respectively.